Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicentre Study to Evaluate the Safety and Efficacy of Zamicastat as Adjunctive Therapy in Long-term Treatment of Pulmonary Arterial Hypertension (PAH) Disease

NCT06009185 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.

NCT NCT06009185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06009185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicentre Study to Evaluate the Safety and Efficacy of Zamicastat as Adjunctive Therapy in Long-term Treatment of Pulmonary Arterial Hypertension (PAH) Disease
Lead sponsor
Bial - Portela C S.A.
Phase
Phase 2
Overall status
Completed
Start date
June 26, 2019
Completion date
February 17, 2022
Enrollment
20 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension